Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 20.

Brüggemann, C; Kirchberger, M C; Goldinger, S M; Weide, B; Konrad, A; Erdmann, M; Schadendorf, D; Croner, R S; Krähenbühl, L; Kähler, K C; Hafner, C; Leisgang, W; Kiesewetter, F; Dummer, R; Schuler, G; Stürzl, M; Heinzerling, L (2017). Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology, 143(10):1977-1984.

Mohr, P; Hauschild, A; Trefzer, U; Enk, A; Tilgen, W; Loquai, C; Gogas, H; Haalck, T; Koller, J; Dummer, R; Gutzmer, R; Brockmeyer, N; Holzle, E; Sunderkotter, C; Mauch, C; Stein, A; Schneider, L A; Podda, M; Goppner, D; Schadendorf, D; Weichenthal, M (2015). Intermittent high-dose intravenous interferon Alfa-2b for adjuvant treatment of stage III melanoma: Final analysis of a randomized phase III dermatologic cooperative oncology group trial. Journal of Clinical Oncology, 33(34):4077-4084.

Schadendorf, D; Amonkar, M M; Milhem, M; Grotzinger, K; Demidov, L V; Rutkowski, P; Garbe, C; Dummer, R; Hassel, J C; Wolter, P; Mohr, P; Trefzer, U; Lefeuvre-Plesse, C; Rutten, A; Steven, N; Ullenhag, G; Sherman, L; Wu, F S; Patel, K; Casey, M; Robert, C (2014). Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Annals of Oncology, 25(3):700-706.

Oberholzer, P A; Kee, D; Dziunycz, P; Sucker, A; Kamsukom, N; Jones, R; Roden, C; Chalk, C J; Ardlie, K; Palescandolo, E; Piris, A; Macconaill, L E; Robert, C; Hofbauer, G F L; McArthur, G A; Schadendorf, D; Garraway, L A (2012). RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors. Journal of Clinical Oncology, 30(3):316-321.

Flaherty, K T; Robert, C; Hersey, P; Nathan, P; Garbe, C; Milhem, M; Demidov, L V; Hassel, J C; Rutkowski, P; Mohr, P; Dummer, R; Trefzer, U; Larkin, J; Utikal, J; Dreno, B; Casey, M; Sherman, L J; Wu, F S; Schadendorf, D (2012). Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group. New England Journal of Medicine, 367(2):107-114.

Eggermont, A M M; Suciu, S; Testori, A; Kruit, W H; Marsden, J; Punt, C J; Santinami, M; Salès, F; Schadendorf, D; Patel, P; Dummer, R; Robert, C; Keilholz, U; Yver, A; Spatz, A (2012). Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. European Journal of Cancer, 48(2):218-225.

Patel, P M; Suciu, S; Mortier, L; Kruit, W H; Robert, C; Schadendorf, D; Trefzer, U; Punt, C J A; Dummer, R; Davidson, N; Becker, Juergen; Conry, R; Thompson, J A; Hwu, W J; Engelen, K; Agarwala, S S; Keilholz, U; Eggermont, A M M; Spatz, A (2011). Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). European Journal of Cancer, 47(10):1476-1483.

Chapman, P B; Hauschild, A; Robert, C; Haanen, J B; Ascierto, P; Larkin, J; Dummer, R; Garbe, C; Testori, A; Maio, M; Hogg, D; Lorigan, P; Lebbe, C; Jouary, T; Schadendorf, D; Ribas, A; O'Day, S J; Sosman, J A; Kirkwood, J M; Eggermont, A M M; Dreno, B; Nolop, K; Li, J; Nelson, B; Hou, J; Lee, R J; Flaherty, K T; McArthur, A G (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 364(26):2507-2516.

Hassel, J C; Sucker, A; Edler, L; Kurzen, H; Moll, I; Stresemann, C; Spieth, K; Mauch, C; Rass, K; Dummer, R; Schadendorf, D (2010). MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. British Journal of Cancer, 103(6):820-826.

Bazhin, A V; Dalke, C; Willner, N; Abschütz, O; Wildberger, H G H; Philippov, P P; Dummer, R; Graw, J; Hrabé de Angelis, M; Schadendorf, D; Umansky, V; Eichmüller, S B (2009). Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy. International Journal of Cancer, 124(1):140-149.

Bottomley, A; Coens, C; Suciu, S; Santinami, M; Kruit, W; Testori, A; Marsden, J; Punt, C; Salès, F; Gore, M; Mackie, R; Kusic, Z; Dummer, R; Patel, P; Schadendorf, D; Spatz, A; Keilholz, U; Eggermont, A (2009). Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. Journal of Clinical Oncology, 27(18):2916-2923.

Gogas, H; Eggermont, A M M; Hauschild, A; Hersey, P; Mohr, P; Schadendorf, D; Spatz, A; Dummer, R (2009). Biomarkers in melanoma. Annals of Oncology, 20(Suppl ):vi8-vi13.

Hersey, P; Bastholt, L; Chiarion-Sileni, V; Cinat, G; Dummer, R; Eggermont, A M M; Espinosa, E; Hauschild, A; Quirt, I; Robert, C; Schadendorf, D (2009). Small molecules and targeted therapies in distant metastatic disease. Annals of Oncology, 20(Suppl ):vi35-vi40.

Hauschild, A; Dummer, R; Ugurel, S; Kaehler, K C; Egberts, F; Fink, W; Both-Skalsky, J; Laetsch, B; Schadendorf, D (2008). Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study. Cancer, 113(6):1404-1411.

Dummer, R; Schadendorf, D (2008). How melanoma is treated in real life. Archives of Dermatology, 144(5):664-665.

Garbe, C; Schadendorf, D; Stolz, W; Volkenandt, M; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R; Hauschild, A (2008). Short German guidelines: malignant melanoma. Journal der Deutschen Dermatologischen Gesellschaft, 6(Suppl ):S9-S14.

Garbe, C; Hauschild, A; Volkenandt, M; Schadendorf, D; Stolz, W; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R (2008). Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Research, 18(2):152-160.

Spieth, K; Kaufmann, R; Dummer, R; Garbe, C; Becker, J C; Hauschild, A; Tilgen, W; Ugurel, S; Beyeler, M; Bröcker, E B; Kaehler, K C; Pföhler, C; Gille, J; Leiter, U; Schadendorf, D (2008). Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the dermatologic cooperative oncology group (DeCOG). Annals of Oncology, 19(4):801-806.

Dummer, R; Hauschild, A; Becker, J C; Grob, J J; Schadendorf, D; Tebbs, V; Skalsky, J; Kaehler, K C; Moosbauer, S; Clark, R; Meng, T C; Urosevic, M (2008). An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clinical Cancer Research, 14(3):856-864.

Garbe, C; Hauschild, A; Volkenandt, M; Schadendorf, D; Stolz, W; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R (2008). Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Research, 18(1):61-67.

This list was generated on Wed Sep 20 00:39:57 2017 CEST.